68Ga-Pentixafor PET detects disease in over two-thirds of FDG-negative multiple myeloma patients

In FDG-avid multiple myeloma, 68Ga-Pentixafor PET/CT detected residual disease in 68% of sites that were FDG-negative, revealing a non-FDG-dependent imaging phenotype that may improve staging. This was a single-center, retrospective analysis.

• Design: Retrospective study of 42 patients with multiple myeloma who underwent both FDG and Pentixafor PET/CT.
• Key secondary finding: The addition of Pentixafor led to a change in disease assessment for a notable subset of patients (exact figure not reported in source).
• Limitation: Single-center, retrospective design with a modest sample size; no histopathologic reference standard for all lesions.

RadPigeon summaries are original and for information only. They are not clinical advice.